Stock MRK MERCK & CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
131.2 USD +0.37% Intraday chart for Merck & Co., Inc. +4.31% +20.34%
05:51pm Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141 MT
05:05pm Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128 MT

Evolution of the average Target Price on Merck & Co., Inc.

Price target over the last 5 years

History of analyst recommendation changes

a657a0b48f11004.7ohlQWBYoftPM4DHT8N5SwXZ2y1_WBaupDQClCmM08Q.2f8UOS4AjIIpSuSDDog3MiiNuGYtMFngy3Nj-VDFifWE0AQOMRHbzX4EuA~92f8cb85f617cbbc832fef8890219d30

Analyst Recommendations on Merck & Co., Inc.

Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141 MT
Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128 MT
Guggenheim Adjusts Price Target on Merck to $146 From $144 MT
Wells Fargo Adjusts Price Target on Merck & Company to $140 From $135 MT
Deutsche Bank Adjusts Price Target on Merck & Company to $140 From $135 MT
JPMorgan Chase Adjusts Price Target on Merck to $145 From $140 MT
Goldman Sachs Raises Price Target on Merck & Company to $144 From $139 MT
Leerink Partners Raises Price Target on Merck & Company to $136 From $132 MT
Truist Lifts Price Target on Merck to $143 From $142, Keeps Buy Rating MT
Jefferies Adjusts Merck & Company Price Target to $150 From $145 MT
Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating MT
BMO Capital Adjusts Price Target on Merck & Company to $148 From $132 MT
Leerink Partners Raises Merck's Price Target to $134 From $129 MT
Zacks Adjusts Price Target on Merck & Company to $132 From $128 MT
Berenberg Raises Price Target on Merck & Company to $143 From $140, Maintains Buy Rating MT
Truist Securities Raises Merck Price Target to $142 From $139, Maintains Buy Rating MT
Wells Fargo Raises Price Target on Merck to $135 From $130, Maintains Equal-Weight Rating MT
Societe Generale Downgrades Merck to Sell From Hold, Raises Price Target to $104 From $103 MT
ANALYST RECOMMENDATIONS : Doordash, Merck, Eli Lilly, Walt Disney, Pearson... Our Logo
UBS Adjusts Merck & Co.'s Price Target to $148 From $135, Maintains Buy Rating MT
Wells Fargo Raises Merck's Price Target to $130 From $125, Maintains Equalweight Rating MT
Truist Securities Raises Merck's Price Target to $139 From $122, Maintains Buy Rating MT
Goldman Sachs Raises Merck's Price Target to $134 From $128, Maintains Buy Rating MT
Barclays Raises Merck's Price Target to $145 From $135, Keeps Overweight Rating MT
Jefferies Raises Merck's Price Target to $140 From $136, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
130.7 USD
Average target price
140.1 USD
Spread / Average Target
+7.19%
High Price Target
155 USD
Spread / Highest target
+18.57%
Low Price Target
114 USD
Spread / Lowest Target
-12.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Merck & Co., Inc.

Cantor Fitzgerald
BMO Capital
Leerink Partners
Zacks Investment Research
Berenberg Bank
Truist Securities
Wells Fargo Securities
Societe Generale
UBS
Goldman Sachs
Barclays
Jefferies & Co.
Deutsche Bank Securities
BofA Securities
TD Cowen
Morgan Stanley
HSBC
Atlantic Equities
Citigroup
Guggenheim
Credit Suisse
JPMorgan Chase
Wolfe Research
SVB Securities LLC
Daiwa Securities
Cowen
SVB Leerink
Argus
RBC Capital Markets
RBC Randall Stanicky
JPMORGAN

Ratings for Merck & Co., Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Consensus Merck & Co., Inc.